American Heart Journal
Volume 159, Issue 3 , Pages 340-347.e1, March 2010

Rivaroxaban—Once daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: Rationale and Design of the ROCKET AF study

  • The Executive Steering Committee, on behalf of the ROCKET AF Study Investigators

      Affiliations

    • Corresponding Author InformationCorresponding author: Manesh R. Patel, MD, Duke Clinical Research Institute, Durham, NC 27705.
    • See Appendix A for a complete listing of The Executive Steering Committee.

Duke Clinical Research Institute, Durham, NC

Received 1 July 2009; accepted 13 November 2009.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 ClinicalTrials.gov no.NCT00403767.

PII: S0002-8703(09)00946-6

doi:10.1016/j.ahj.2009.11.025

American Heart Journal
Volume 159, Issue 3 , Pages 340-347.e1, March 2010

Article Tools

* Image Usage & Resolution